Torre L, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
Article
Google Scholar
Brustugun OT, Møller B, Helland A. Years of life lost as a measure of cancer burden on a national level. Br J Cancer. 2014;111:1014–20. https://doi.org/10.1038/bjc.2014.364.
Article
CAS
PubMed
PubMed Central
Google Scholar
Planchard D, Popat S, Kerr K, Novello S, Smit E., Faivre-Finn C, et al. Metastatic non-small cell lung cancer : ESMO Clinical Practice Guidelines for diagnosis , treatment Clinical Practice Guidelines. 2019;29 October 2018.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–54.
Article
CAS
Google Scholar
Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, et al. TP53 mutation spectrum in smokers and never smoking lung cancer patients. Front Genet. 2016;7:85 may:1–10.
Article
Google Scholar
Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019;28:1370–1384.e5. https://doi.org/10.1016/j.celrep.2019.07.001.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127–33. https://doi.org/10.1038/ng.2762.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134–40. https://doi.org/10.1038/ng.2760.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
Article
CAS
Google Scholar
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893–8. https://doi.org/10.1038/nature06358.
Article
CAS
PubMed
PubMed Central
Google Scholar
Staaf J, Isaksson S, Karlsson A, Jönsson M, Johansson L, Jönsson P, et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer. 2013;132:2020–31. https://doi.org/10.1002/ijc.27879.
Article
CAS
PubMed
Google Scholar
Vollan HKM, Rueda OM, Chin S, Turashvili G, Shah S, Lingjærde OC, et al. A tumor DNA complexity index is an independent predictor of survival in breast and ovarian cancer. Mol Oncol. 2014;9:1–39.
Google Scholar
Blons H, Pallier K, Le Corre D, Danel C, Tremblay-Gravel M, Houdayer C, et al. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genet. 2008;1:1–25. doi:1755-8794-1-25 [pii]. https://doi.org/10.1186/1755-8794-1-25.
Article
CAS
Google Scholar
Fong Y, Lin Y-S, Liou C-P, Li C-F, Tzeng C-C. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology. 2010;15:700–5.
Article
Google Scholar
Planck M, Isaksson S, Veerla S, Staaf J. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome. Clin Cancer Res. 2013;19:5116–26. https://doi.org/10.1158/1078-0432.CCR-13-0928.
Article
CAS
PubMed
Google Scholar
Shao X, Lv N, Liao J, Long J, Xue R, Ai N, et al. Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet. 2019;20:1–14.
Article
Google Scholar
Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL. An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Syst Biol. 2010;4:67.
Article
Google Scholar
Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An integrated approach to uncover drivers of cancer. Cell. 2010;143:1005–17. https://doi.org/10.1016/j.cell.2010.11.013.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bjaanæs MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, et al. Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas. Int J Cancer. 2014;135:1812–21. https://doi.org/10.1002/ijc.28828.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, et al. Genome-wide DNA methylation analyses in lung adenocarcinomas: association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. Mol Oncol. 2015. https://doi.org/10.1016/j.molonc.2015.10.021.
Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH. Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn Mol Pathol. 2012;20:158–65. https://doi.org/10.1097/PDM.0b013e31820b49e2.
Article
CAS
Google Scholar
Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, et al. PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007;17:1665–74.
Article
CAS
Google Scholar
The Wellcome Trust Case Control Consortium*. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.
Article
Google Scholar
The international HapMap consortium*. The International HapMap Project. Nature. 2003;426(6968):789–96. https://doi.org/10.1038/nature02168.
Article
CAS
Google Scholar
Durbin RM, Altshuler DL, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1064–7073. https://doi.org/10.1038/nature09534.
Article
CAS
Google Scholar
Diskin SJ, Li M, Hou C, Yang S, Glessner J, Hakonarson H, et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res. 2008;36:1–12.
Article
Google Scholar
Nilsen G, Liestøl K, Van Loo P, Moen Vollan HK, Eide MB, Rueda OM, et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics. 2012;13:1–16. https://doi.org/10.1186/1471-2164-13-591.
Article
CAS
Google Scholar
Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010;107:16910–5. doi:1009843107 [pii]. https://doi.org/10.1073/pnas.1009843107.
Article
PubMed
PubMed Central
Google Scholar
Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, et al. DNA copy number motifs are strong and independent predictors of survival in breast cancer. Commun Biol. 2020;3:1–9.
Article
Google Scholar
Core R. Team. R : a language and environment for statistical. Computing. 2014;1. https://doi.org/10.1007/978-3-540-74686-7.
Han X, Tan Q, Yang S, Li J, Xu J, Hao X, et al. Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma. Front Oncol. 2019;9:1–10.
Article
Google Scholar
Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res. 2009;69:1055–62.
Article
Google Scholar
Eischen CM, Lozano G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat. 2014;35:728–37. https://doi.org/10.1002/humu.22524.
Article
CAS
PubMed
PubMed Central
Google Scholar
Berger AH, Imielinski M, Duke F, Wala J, Kaplan N, Shi G-X, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014;33(35):4418–23 November 2013:1–6. https://doi.org/10.1038/onc.2013.581.
Article
CAS
PubMed
PubMed Central
Google Scholar
Diaz-Garcia CV. Agudo-Lopez a., Perez C, Lopez-Martin J a., Rodriguez-Peralto JL, de Castro J, et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013;34:1031–8. https://doi.org/10.1093/carcin/bgt022.
Article
CAS
PubMed
Google Scholar
Czubak K, Lewandowska MA, Klonowska K, Kowalewski J, Figlerowicz M, Kozlowski P. High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer. Oncotarget. 2015;6:23399–416.
Article
Google Scholar
Varella-Garcia M. Chromosomal and genomic changes in lung cancer. Cell Adh Migr. 2009;4:100–6. https://doi.org/10.4161/cam.4.1.10884.
Article
Google Scholar
Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018;33:676–689.e3.
Article
CAS
Google Scholar
AL Zeyadi M, Dimova I, Ranchich V, Rukova B, Nesheva D, Hamude Z, et al. Whole genome microarray analysis in non-small cell lung cancer. Biotechnol Biotechnol Equip 2015;29:111–118. doi:https://doi.org/10.1080/13102818.2014.989179.
Silwal-Pandit L, Vollan HKM, Chin SF, Rueda OM, McKinney S, Osako T, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20:3569–80.
Article
CAS
Google Scholar
Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820–3.
Article
Google Scholar
Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, et al. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 2019;132:65–71. https://doi.org/10.1016/j.lungcan.2019.04.005.
Article
PubMed
Google Scholar
Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non–small-cell lung Cancer. N Engl J Med. 2005;353:123–32.
Article
CAS
Google Scholar
Hirsch FR. Varella-Garcia M, Bunn P a, Di Maria M V, Veve R, Bremmes RM, et al. epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–807.
Article
CAS
Google Scholar
Hirsch FR. Paz- L, Mok TS, Jänne P a, Eberhardt WE, Cappuzzo F, et al. epidermal growth factor receptor inhibition in lung Cancer status 2012. J Thorac Oncol. 2013;8:373–84. https://doi.org/10.1097/JTO.0b013e31827ed0ff.
Article
CAS
PubMed
Google Scholar
Yuan S, Yu SL, HYWHWY C, Hsu YC, Su KY, HYWHWY C, et al. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J Clin Oncol. 2011;29:3435–42. doi:JCO.2011.35.3979 [pii]. https://doi.org/10.1200/JCO.2011.35.3979.
Article
CAS
PubMed
Google Scholar
Planck M, Edlund K, Botling J, Micke P, Isaksson S, Staaf J. Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status. PLoS One. 2013;8:1–14.
Article
Google Scholar
Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006;66:6050–62. https://doi.org/10.1158/0008-5472.CAN-05-4618.
Article
CAS
PubMed
Google Scholar
Heidenblad M, Lindgren D. Veltman J a, Jonson T, Mahlamäki EH, Gorunova L, et al. microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene. 2005;24:1794–801.
Article
CAS
Google Scholar
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma. J Thorac Oncol. 2015;10:768–77. https://doi.org/10.1097/JTO.0000000000000516.
Article
CAS
PubMed
PubMed Central
Google Scholar
Collisson E A., Campbell JD, brooks AN, Berger AH, lee W, Chmielecki J, et al. comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550. doi:https://doi.org/10.1038/nature13385, 7511.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alpha or both for advanced renal cell carcinoma. N Engl J Med. 2007;356:2271–81.
Article
CAS
Google Scholar
Vansteenkiste J, Canon J-L, De Braud F, Grossi F, De Pas T, Gray J, et al. Safety and efficacy of Buparlisib (BKM120) in patients with untreated squamous non-small cell lung Cancer. J Thorac Oncol. 2015;10:1319–27. https://doi.org/10.1097/JTO.0000000000000607.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun Z, Wang Z, Liu X, Wang D. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anti-Cancer Drugs. 2015;1:1–14. https://doi.org/10.1097/CAD.0000000000000172.
Article
CAS
Google Scholar
Ekman S, Wynes MW, Hirsch FR. The mTOR pathway in lung Cancer and implications for therapy and biomarker analysis. J Thorac Oncol. 2012;7:947–53.
Article
CAS
Google Scholar
Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, et al. Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in Cancer patients. Mol Cancer Ther. 2018;18:448–58.
Article
Google Scholar